LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients-Reference-Cited by-同舟云学术

LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients

Published:2016-03-18 Issue:2 Volume:139 Page:424-432
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Mock Andreas¹²³⁴,Geisenberger Christoph¹,Orlik Christian¹,Warta Rolf¹,Schwager Christian³⁴,Jungk Christine¹,Dutruel Céline²,Geiselhart Lea²,Weichenhan Dieter²,Zucknick Manuela⁵⁶,Nied Ann-Katrin¹,Friauf Sara¹,Exner Janina¹,Capper David⁷⁸,Hartmann Christian⁷⁹,Lahrmann Bernd¹⁰¹¹¹²,Grabe Niels¹⁰¹¹,Debus Jürgen⁴,von Deimling Andreas⁷⁸,Popanda Odilia²,Plass Christoph²,Unterberg Andreas¹,Abdollahi Amir³⁴,Schmezer Peter²,Herold-Mende Christel¹

Affiliation:

1. Division of Experimental Neurosurgery, Department of Neurosurgery; Heidelberg University Hospital; Heidelberg Germany

2. Division of Epigenomics and Cancer Risk Factors; German Cancer Research Center (DFKZ); Heidelberg Germany

3. Molecular and Translational Radiation Oncology; National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ); Heidelberg Germany

4. Heidelberg Institute for Radiation Oncology (HIRO), Heidelberg Ion Therapy Center (HIT), Department of Radiation Oncology; Heidelberg University Hospital; Heidelberg Germany

5. Division of Biostatistics; German Cancer Research Center (DKFZ); Heidelberg Germany

6. Oslo Center for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences; University of Oslo; Oslo Norway

7. Department of Neuropathology; Heidelberg University Hospital; Heidelberg Germany

8. German Cancer Consortium (DKTK), Clinical Cooperation Unit Neuropathology; German Cancer Research Center (DFKZ); Heidelberg Germany

9. Department of Neuropathology, Institute of Pathology; Hannover Medical School; Hannover Germany

10. Hamamatsu Tissue Imaging and Analysis Center (TIGA), BIOQUANT; University of Heidelberg; Heidelberg Germany

11. National Center for Tumor Diseases (NCT), Medical Oncology; Heidelberg University Hospital; Heidelberg Germany

12. Institute of Pathology; Heidelberg University Hospital; Heidelberg Germany

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ijc.30069/fullpdf

Reference31 articles.

1. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas;Ohgaki;J Neuropathol Exp Neurol,2005

2. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;Stupp;N Engl J Med,2005

3. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial;Stupp;Lancet Oncol,2009

4. Long-term survival with glioblastoma multiforme;Krex;Brain,2007

5. Identification of expressed genes characterizing long-term survival in malignant glioma patients;Yamanaka;Oncogene,2006

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of ADCY1 in Regulating the Sensitivity of Platinum-Based Chemotherapy in NSCLC;Pharmaceuticals;2024-08-24

2. Role of DNA methylation in the relationship between glioma risk factors and glioma incidence: a two-step Mendelian randomization study;Scientific Reports;2023-04-21

3. Transcriptomic Profiling Revealed Lnc-GOLGA6A-1 as a Novel Prognostic Biomarker of Meningioma Recurrence;Neurosurgery;2022-05-16

4. A Novel Ferroptosis-Based Molecular Signature Associated with Biochemical Recurrence-Free Survival and Tumor Immune Microenvironment of Prostate Cancer;Frontiers in Cell and Developmental Biology;2022-01-06

5. Mitochondria-targeting nano therapy altering IDH2-mediated EZH2/EZH1 interaction as precise epigenetic regulation in glioblastoma;Biomaterials Science;2022